Details of the Drug

General Information of Drug (ID: DMAB9QE)

Drug Name
Nivolumab
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [2]
Esophageal cancer 2B70 Phase 3 [3]
Gastric adenocarcinoma 2B72 Phase 3 [3]
Malignant pleural mesothelioma 2C26.0 Phase 3 [3]
Multiple myeloma 2A83 Phase 3 [3]
Recurrent glioblastoma 2A00.00 Phase 3 [3]
Small-cell lung cancer 2C25.Y Phase 3 [3]
Central nervous system lymphoma 2B33.5 Phase 2 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Diffuse large B-cell lymphoma 2A81 Phase 2 [3]
Follicular lymphoma 2A80 Phase 2 [3]
Prostate cancer 2C82.0 Phase 2 [3]
Ovarian cancer 2C73 Phase 1/2 [3]
Pancreatic cancer 2C10 Phase 1/2 [3]
Triple negative breast cancer 2C60-2C65 Phase 1/2 [3]
Chronic myelogenous leukaemia 2A20.0 Phase 1 [3]
Renal cell carcinoma 2C90 Application submitted [3]
Lung squamous cell carcinoma 2C25.2 Investigative [5]
⏷ Show the Full List of Indication(s)
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYY
ADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPS
VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLGK
>light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Cross-matching ID
DrugBank ID
DB09035
TTD ID
D00GOV
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nivolumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Nivolumab and Deflazacort. Muscular dystrophy [8C70] [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
5 The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules. 2021 Mar 5;26(5):1392.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".